Objectives: To analyze the feasibility of DWI-MRI and ADC to evaluate treatment response in patients with multiple myeloma (MM). To correlate the variations of ADC and SUVmax in F-FDG PET-CT.
Methods: 27 patients with MM that had a whole-body MRI and F-FDG PET-CT performed at baseline and after treatment were retrospectively recruited between February 2018 and May 2020.